Otsuka announces NICE recommendation of Lupkynis® (voclosporin) with mycophenolate mofetil for treating active lupus nephritis LONDON, UK, 3 May 2023 – Otsuka Pharmaceuticals (U.K.) Ltd. announces that the National Institute for Health and C.